Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

AD Ports, Hayat Biotech ink deal

AD Ports Group operates one of the largest supply chains in the gulf region. (WAM)
  • The partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centers around the globe.
  • The deal encapsulates shipping of strategic construction supplies, including containers, machinery, raw materials.

AD Ports Group and Hayat Biotech signed a deal to support Hayat Biotech’s global logistics and distribution efforts through AD Ports Group’s advanced pharma logistics network, which includes its cold & ultra-cold pharma hub based in KIZAD.

Specifically, the partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centers around the globe and provide logistics solutions to serve its international markets.

The deal encapsulates shipping of strategic construction supplies, including containers, machinery, raw materials, and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities.

Once fully completed, the facilities will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced COVID-19 vaccine in the UAE and the Arab world.

As part of the collaboration, the distribution will be handled by the HOPE Consortium, an Abu Dhabi-led partnership which operates one of the largest and most complete end-to-end pharma supply chains on the market today.

Last year, Hayat Biotech announced the development of a purpose-built research and development hub for life sciences, biotechnology and vaccine production.

Set up in KIZAD, the facility will be capable of producing over 200 million vaccine doses annually.

AD Ports Group operates one of the largest supply chains in the region supporting multiple industry sectors, including construction and pharma.